Dexcom Inc (NASDAQ: DXCM) has a higher price-to-earnings ratio of 47.30x compared to its average ratio, The 36-month beta value for DXCM is at 1.43. Analysts have varying views on the stock, with 18 analysts rating it as a “buy,” 5 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for DXCM is 386.62M, and currently, shorts hold a 2.85% of that float. The average trading volume for DXCM on April 15, 2025 was 4.29M shares.
DXCM) stock’s latest price update
Dexcom Inc (NASDAQ: DXCM) has experienced a rise in its stock price by 1.89 compared to its previous closing price of 66.14. However, the company has seen a gain of 9.35% in its stock price over the last five trading days. zacks.com reported 2025-04-11 that DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding diabetes care access.
DXCM’s Market Performance
DXCM’s stock has risen by 9.35% in the past week, with a monthly drop of -4.67% and a quarterly drop of -15.59%. The volatility ratio for the week is 7.43% while the volatility levels for the last 30 days are 4.89% for Dexcom Inc. The simple moving average for the past 20 days is -1.37% for DXCM’s stock, with a -14.51% simple moving average for the past 200 days.
Analysts’ Opinion of DXCM
Many brokerage firms have already submitted their reports for DXCM stocks, with Mizuho repeating the rating for DXCM by listing it as a “Outperform.” The predicted price for DXCM in the upcoming period, according to Mizuho is $85 based on the research report published on April 10, 2025 of the current year 2025.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see DXCM reach a price target of $115, previously predicting the price at $85. The rating they have provided for DXCM stocks is “Buy” according to the report published on February 03rd, 2025.
Robert W. Baird gave a rating of “Outperform” to DXCM, setting the target price at $104 in the report published on January 16th of the current year.
DXCM Trading at -12.96% from the 50-Day Moving Average
After a stumble in the market that brought DXCM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.60% of loss for the given period.
Volatility was left at 4.89%, however, over the last 30 days, the volatility rate increased by 7.43%, as shares sank -5.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.39% lower at present.
During the last 5 trading sessions, DXCM rose by +9.35%, which changed the moving average for the period of 200-days by -40.63% in comparison to the 20-day moving average, which settled at $68.33. In addition, Dexcom Inc saw -13.35% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DXCM starting from Heller Bridgette P, who sale 352 shares at the price of $70.33 back on Mar 17 ’25. After this action, Heller Bridgette P now owns 22,997 shares of Dexcom Inc, valued at $24,756 using the latest closing price.
Heller Bridgette P, the Director of Dexcom Inc, proposed sale 352 shares at $70.33 during a trade that took place back on Mar 17 ’25, which means that Heller Bridgette P is holding shares at $24,756 based on the most recent closing price.
Stock Fundamentals for DXCM
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.6 for the gross margin
The net margin for Dexcom Inc stands at 0.14. The total capital return value is set at 0.17. Equity return is now at value 27.63, with 9.04 for asset returns.
Based on Dexcom Inc (DXCM), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at 0.39. The debt to equity ratio resting at 1.2. The interest coverage ratio of the stock is 31.58.
Currently, EBITDA for the company is 840.7 million with net debt to EBITDA at 2.1. When we switch over and look at the enterprise to sales, we see a ratio of 7.03. The receivables turnover for the company is 3.9for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.47.
Conclusion
In conclusion, Dexcom Inc (DXCM) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
